Lopiano Sofia, Guarrera James V, Lunsford Keri E
Division of Transplant and HPB Surgery, Department of Surgery, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.
Curr Oncol. 2025 May 22;32(6):293. doi: 10.3390/curroncol32060293.
Optimal curative therapy for intrahepatic cholangiocarcinoma (iCCA) involves hepatic resection; however, due to its insidious nature, iCCA frequently presents at advanced stages. Consequently, 70-80% of patients feature unresectable iCCA at presentation. Recent expansions in therapeutic options for locally advanced unresectable iCCA include immunotherapy, targeted chemotherapeutics, and liver-directed therapies. These have increased progression-free survival, enhanced response rates, and improved downstaging for resection. Liver transplant has also emerged as an alternative for patients whose tumors remain unresectable despite therapeutic response. Here, we explore emerging treatment options included in a multidisciplinary treatment paradigm to prolong survival in patients with initially unresectable locally advanced iCCA.
肝内胆管癌(iCCA)的最佳根治性治疗方法是肝切除术;然而,由于其隐匿性,iCCA常常在晚期才出现。因此,70%-80%的患者在初诊时就表现为不可切除的iCCA。近期,针对局部晚期不可切除iCCA的治疗选择有所扩展,包括免疫疗法、靶向化疗药物以及肝脏定向治疗。这些治疗方法提高了无进展生存期,提升了缓解率,并改善了切除的降期情况。对于那些尽管经过治疗仍无法切除肿瘤的患者,肝移植也已成为一种替代选择。在此,我们探讨多学科治疗模式中包含的新兴治疗选择,以延长初诊时为局部晚期不可切除iCCA患者的生存期。